Unresectable Colorectal Liver Metastases: Percutaneous Ablation Using CT-Guided High-Dose-Rate Brachytherapy (CT-HDBRT)

Abstract

Purpose: To evaluate the clinical outcome of CT-guided high-dose-rate brachytherapy (CT-HDRBT) of unresectable colorectal liver metastases (CRLMs).

Materials and Methods: Retrospective analysis of all consecutive patients with unresectable CRLMs treated with CT-HDRBT between January 2008 and November 2012. Treatment was performed by CT-guided catheter placement and high-dose-rate brachytherapy with an iridium-192 source. MRI follow-up was performed after 6 weeks and then every 3 months post-intervention. The primary endpoint was local tumor control (LTC); secondary endpoints included time to progression (TTP) and overall survival (OS).

Results: 80 heavily pretreated patients with 179 metastases were available for MRI evaluation for a mean follow-up time of 16.9 months. The mean tumor diameter was 28.5 mm (range: 8 – 107 mm). No major complications were observed. A total of 23 (12.9 %) local tumor progressions were observed. Lesions ≥ 4 cm in diameter showed significantly more local progression than smaller lesions (< 4 cm). 50 patients (62.5 %) experienced systemic tumor progression. The median TTP was 6 months. 28 (43 %) patients died during the follow-up period. The median OS after ablation was 18 months.

Conclusion: CT-HDRBT is an effective technique for the treatment of unresectable CRLMs and warrants promising LTC rates compared to thermal ablative techniques. A combination with other local and systemic therapies should be evaluated in patients with lesions > 4 cm in diameter, in which higher progression rates are expected.

Key Points:

• CT-HDRBT enables a highly cytotoxic irradiation of colorectal liver metastases with simultaneous conservation of important neighboring structures (eg liver parenchyma, bile ducts and bowel)

• The local tumor control rates obtained by CT-HDRBT in patients with colorectal liver metastases are promising, also compared to the local tumor control rates after RFA

• Metastases with a diameter of 4 cm or abow, display a higher local progression rate after CT-HDRBT, therefor a combination therapy with other locoregional or systemic treatments should be investigated in prospective studies

Citation Format:

• Collettini F, Lutter A, Schnapauff D et al. Unresectable Colorectal Liver Metastases: Percutaneous Ablation Using CT-Guided High-Dose-Rate Brachytherapy (CT-HDBRT). Fortschr Röntgenstr 2014; 186: 606 – 612

Zusammenfassung

Ziel: Evaluierung der Behandlungsergebnisse der CT-gesteuerten Hochdosisbrachytherapie (CT-HDRBT) bei irresektablen kolorektalen Lebermetastasen (CRLM).

Material und Methoden: Retrospektive Analyse von allen konsekutiven Patienten mit irresektablen CRLM, die zwischen Januar 2008 und November 2012 mittels CT-HDRBT behandelt wurden. Die Behandlung erfolgte über eine CT-gesteuerte Hochdosisbrachytherapie mittels einer Iridium-192-Quelle. Post interventionelle Kontrollen erfolgten durch kontrastverstärkte MRT-Untersuchungen nach 6 Wochen nach Ablation und anschließend alle 3 Monate. Als primärer Endpunkt wurde die lokale Tumorkontrolle festgelegt. Als sekundäre Endpunkte wurden das progressionsfreie Intervall und das Gesamtüberleben nach Ablation untersucht.

Ergebnisse: 80 zumeist intensiv vorbehandelte Patienten mit 179 irresektablen Lebermetastasen konnten eingeschlossen werden. Die mittlere Verlaufskontrollzeit betrug 16,9 Monate. Der mittlere Durchmesser der Metastasen betrug 28,5 mm (8 – 107 mm). Es traten keinerlei Komplikationen auf. 23 Metastasen (12,8 %) entwickelten eine lokale Progression. Metastasen ≥ 4 cm im Diameter zeigten eine signifikant höhere lokale Progressionsrate als kleinere Metastasen (< 4 cm). Bei 50 Patienten (62,5 %) zeigte sich im Verlauf ein Voranschreiten der Tumorerkrankung in Form eines nicht lokalen intrahepatischen oder extrahepatischen Tumorprogress. Das mediane progressionsfreie Überleben lag bei 6 Monaten. 28 Patienten (43 %) starben während des Follow-ups. Das mediane Gesamtüberleben nach Ablation betrug 18 Monate.

Schlussfolgerungen: Die CT-HDRBT ist eine aussichtsreiche Technik zur Ablation von CRLM mit der man, im Vergleich zu den thermischen Ablationsverfahren, sehr vielversprechende lokale Tumorkontrollraten erzielen kann. Bei Läsionen mit einem Durchmesser > 4 cm, bei denen höhere Progressionsrate zu erwarten sind, sollte eine Kombination mit anderen lokalen oder systemischen Therapien erwogen werden. Dies gilt es in weiteren klinischen Studien zu untersuchen.

Key words

abdomen - ablation procedures - interventional procedures - metastases - radiofrequency (RF) ablation

• References

• 1 Robert Koch-Institut (Hrsg) Sterblichkeit, Todesursachen und regionale Unterschiede. Gesundheitsberichterstattung des Bundes. Heft 52. Berlin: RKI; 2011
• 2 Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 22 (371) 1007-1016
• 3 Schindl M, Gruenberger Th, Längle F. Current strategies in the treatment of colorectal cancer liver metastases: aspects of surgical treatment. European Surgery 2008; 16: 332-336
• 4 Garden OJ, Rees M, Poston GJ et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 : (Suppl 3): iii1-iii8
• 5 Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
• 6 Adam R, Wicherts DA, de Haas RJ et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. Journal of Clinical Oncology 2009; 27: 1829-1835
• 7 Solbiati L, Ierace T, Goldberg SN et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997; 202: 195-203
• 8 Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221: 159-166
• 9 Livraghi T, Solbiati L, Meloni F et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer 2003; 15 (97) 3027-3035
• 10 Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. European Radiolology 2004; 14: 2261-2267
• 11 Jakobs TF, Hoffmann RT, Trumm C et al. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 2006; 26: 671-680
• 12 Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48: 253-258
• 13 Veltri A, Sacchetto P, Tosetti I et al. Radiofrequency ablation of colorectal liver metastases: small size favourably predicts technique effectiveness and survival. Cardiovascular Interventional Radiolology 2008; 31: 948-956
• 14 Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. Journal of Vascular and Interventional Radiology 2008; 19: 712-717
• 15 Veltri A, Guarnieri T, Gazzera C et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med 2012; 117: 1139-1151
• 16 Solbiati L, Ahmed M, Cova L et al. Small Liver Colorectal Metastases Treated with Percutaneous Radiofrequency Ablation: Local Response Rate and Long-term Survival with Up to 10-year Follow-up. Radiology 2012; 265: 958-968
• 17 Ruers T, Punt C, Van Coevorden F et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23: 2619-2626
• 18 Mulier S, Ni Y, Jamart J et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Annals of Surgery 2005; 242: 158-171
• 19 Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol 2011; 21: 287-293
• 20 Ricke J, Mohnike K, Pech M et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485
• 21 Collettini F, Schnapauff D, Poellinger A et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours. Eur Radiol 2012; 22: 1101-1109
• 22 Ricke J, Thormann M, Ludewig M et al. MR-guided liver tumor ablation employing open high-field 1.0 T MRI for image-guided brachytherapy. Eur Radiol 2010; 20: 1985-1993
• 23 Goldberg SN, Grassi CJ, Cardella JF. for the Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation. et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20: S377-S390
• 24 Lu DS, Raman SS, Vodopich DJ et al. Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the “heat sink” effect. Am J Roentgenol Am J Roentgenol 2002; 178: 47-51
• 25 Li Y, Brown RE, Martin RC. Incomplete thermal ablation of hepatocellular carcinoma: effects on tumor proliferation. J Surg Res 2013; 181: 250-255
• 26 Kennedy AS, Coldwell D, Nutting C et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425
• 27 Jakobs TF, Hoffmann RT, Dehm K et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19: 1187-1195
• 28 der Pool AE, Méndez RomeroA, Wunderink W et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010; 97: 377-382
• 29 Bae SH, Kim MS, Cho CK et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012; 106: 138-143
• 30 Scorsetti M, Arcangeli S, Tozzi A et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013; 86: 336-342
• 31 Berber B, Ibarra R, Snyder L et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB 2013; DOI: 10.1111/hpb.12044.
• 32 Mohnike K, Wieners G, Schwartz F et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179
• 33 Wieners G, Mohnike K, Peters N et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – a phase II-study. Radiother Oncol 2011; 100: 314-319
• 34 Collettini F, Golenia M, Schnapauff D et al. Percutaneous computed tomography-guided high-dose-rate brachytherapy ablation of breast cancer liver metastases: initial experience with 80 lesions. J Vasc Interv Radiol 2012; 23: 618-626